This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:SONN

Sonnet BioTherapeutics (SONN) Stock Price, News & Analysis

Sonnet BioTherapeutics logo

About Sonnet BioTherapeutics Stock (NASDAQ:SONN)

Key Stats

Today's Range
$1.26
▼
$3.23
50-Day Range
$1.02
▼
$5.92
52-Week Range
$1.08
▼
$19.30
Volume
10.08 million shs
Average Volume
2.09 million shs
Market Capitalization
$7.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage biotechnology company dedicated to developing innovative cytokine-based therapeutics for oncology and autoimmune disorders. The company’s platform centers on engineering human cytokines, notably interleukin-2 and related molecules, fused to carrier proteins such as human serum albumin. This design aims to extend circulating half-life, enhance tumor localization, and minimize systemic toxicity compared with traditional cytokine therapies.

Sonnet’s lead pipeline candidates are in early-phase clinical trials for the treatment of solid tumors, where the company seeks to demonstrate improved efficacy and safety. In parallel, Sonnet is advancing preclinical immunocytokine programs targeting specific aspects of the tumor microenvironment to further leverage its fusion protein technology across multiple cancer indications.

Headquartered in San Diego, California, Sonnet BioTherapeutics conducts research and development operations in the United States. The management team comprises seasoned industry professionals with expertise in immuno-oncology, biologics development, and clinical strategy, positioning the company to progress its pipeline toward later-stage trials and potential partnerships.

AI Generated. May Contain Errors.

Receive SONN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sonnet BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SONN Stock News Headlines

432 miles southeast of Washington, DC…
Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip maker for nearly four decades, including AMD, Intel, NVIDIA, Samsung and Taiwan Semiconductor. Washington is set to declare it a national strategic resource and ban its export. Apple, NVIDIA and Amazon have committed over $2 trillion, and Morgan Stanley estimates a $10 trillion economic boom. One small U.S. mining company sits at the center of it.tc pixel
Hyperliquid Wants $1B to Power Its Next HYPE Token Expansion
See More Headlines

SONN Stock Analysis - Frequently Asked Questions

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) issued its quarterly earnings results on Wednesday, August, 13th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by $0.46.

Sonnet BioTherapeutics shares reverse split on the morning of Sunday, September 29th 2024.The 1-8 reverse split was announced on Sunday, September 29th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, September 29th 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Sonnet BioTherapeutics investors own include NIO (NIO), Ocugen (OCGN), Tesla (TSLA), SNDL (SNDL), Zomedica (ZOM), Tonix Pharmaceuticals (TNXP) and Advanced Micro Devices (AMD).

Company Calendar

Today
11/19/2026
Fiscal Year End
9/30/2027

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:SONN
CIK
1106838
Employees
10
Year Founded
2011

Profitability

EPS (Trailing Twelve Months)
($8.05)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$7.44 million
Net Margins
N/A
Pretax Margin
-1,339.60%
Return on Equity
-4,646.10%
Return on Assets
-342.21%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.26
Quick Ratio
0.26

Sales & Book Value

Annual Sales
$1 million
Price / Sales
7.18
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.71) per share
Price / Book
-1.43

Miscellaneous

Outstanding Shares
7,078,000
Free Float
6,478,000
Market Cap
$7.18 million
Optionable
Not Optionable
Beta
1.48

Social Links

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

This page (NASDAQ:SONN) was last updated on 12/2/2025 by MarketBeat.com Staff.
From Our Partners